# Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer

Source: https://onco.cc/trials/nct06717464/  
OnCo record `nct06717464` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of toripalimab and capecitabine in gallbladder cancer and other biliary tract cancers, run by Tianjin Medical University Cancer Institute and Hospital, active and no longer recruiting.

## Summary

Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer is a phase 2, randomised interventional study registered as NCT06717464 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 110 participants, started 2024-11-12 and due to reach its primary completion in 2026-12-31. Interventions recorded: Capecitabine, Toripalimab. Conditions listed: Gallbladder Cancer, Hilar Cholangiocarcinoma, Distal Cholangiocarcinoma. Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-24
- Tags: ctgov-ingest; gallbladder-deep-dive
- Registry id: NCT06717464
- Phase: 2
- Setting: Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer, Phase II, Single-center, Randomized Controlled Trial
- Sponsor: Tianjin Medical University Cancer Institute and Hospital
- Enrolled: 110

## Sources

- ClinicalTrials.gov NCT06717464: https://clinicaltrials.gov/study/NCT06717464

## Connected records

- cancers: [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Extrahepatic cholangiocarcinoma (perihilar and distal)](https://onco.cc/cancers/extrahepatic-cholangiocarcinoma/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Toripalimab](https://onco.cc/drugs/toripalimab/)
- terms: [Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)](https://onco.cc/terms/gallbladder-cancer-in-biliary-trials/)

---
JSON: https://onco.cc/api/v1/entities/nct06717464.json